The Cancer Letter says FDA guidance on minimal residual disease in multiple myeloma matters most beyond the ODAC vote, consolidating trial design updates for developers.
FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare